STUDY OBJECTIVES: To investigate potential stimulant and anticataplectic effects of 10 mg reboxetine in patients diagnosed with narcolepsy. DESIGN: 12 patients were treated for a 2-week period with 10 mg reboxetine under open conditions. The dosage of reboxetine was gradually increased between Day 1 and Day 9. Outcome parameters consisted of nightime polysomnography (PSG), Multiple Sleep Latency Test (MSLT), Epworth Sleepiness Scale (ESS), Visual Analog Scale for Sleepiness (VAS), Ullanlinna Narcolepsy Scale (UNS), and the Beck Depression Inventory (BDI). SETTING: Sleep Disorders Clinic at a University Hospital. PATIENTS: 12 patients meeting ICSD-criteria for narcolepsy. INTERVENTIONS: Pharmacological treatment with reboxetine. RESULTS: Following treatment for two-weeks, a significant improvement in daytime sleepiness could be observed, as reflected by a mean decrease of 48.6% on the Epworth Sleepiness Scale and a mean increase of 54.7% in sleep latency on the MSLT. Furthermore, a significant reduction in the cataplexy subscore of the Ullanlinna Narcolepsy Scale and in REM-sleep was found. CONCLUSIONS: Our results suggest that reboxetine exerts stimulant and anticataplectic effects in narcolepsy. Contrary to previous thinking, by which stimulant action would require dopaminergic facilitation, noradrenergic mechanisms might be relevant to the control of wakefulness.
STUDY OBJECTIVES: To investigate potential stimulant and anticataplectic effects of 10 mg reboxetine in patients diagnosed with narcolepsy. DESIGN: 12 patients were treated for a 2-week period with 10 mg reboxetine under open conditions. The dosage of reboxetine was gradually increased between Day 1 and Day 9. Outcome parameters consisted of nightime polysomnography (PSG), Multiple Sleep Latency Test (MSLT), Epworth Sleepiness Scale (ESS), Visual Analog Scale for Sleepiness (VAS), Ullanlinna Narcolepsy Scale (UNS), and the Beck Depression Inventory (BDI). SETTING: Sleep Disorders Clinic at a University Hospital. PATIENTS: 12 patients meeting ICSD-criteria for narcolepsy. INTERVENTIONS: Pharmacological treatment with reboxetine. RESULTS: Following treatment for two-weeks, a significant improvement in daytime sleepiness could be observed, as reflected by a mean decrease of 48.6% on the Epworth Sleepiness Scale and a mean increase of 54.7% in sleep latency on the MSLT. Furthermore, a significant reduction in the cataplexy subscore of the Ullanlinna Narcolepsy Scale and in REM-sleep was found. CONCLUSIONS: Our results suggest that reboxetine exerts stimulant and anticataplectic effects in narcolepsy. Contrary to previous thinking, by which stimulant action would require dopaminergic facilitation, noradrenergic mechanisms might be relevant to the control of wakefulness.
Authors: Carrie E Mahoney; Lindsay J Agostinelli; Jessica N K Brooks; Bradford B Lowell; Thomas E Scammell Journal: J Neurosci Date: 2017-02-24 Impact factor: 6.167
Authors: Yves Dauvilliers; Jerry M Siegel; Regis Lopez; Zoltan A Torontali; John H Peever Journal: Nat Rev Neurol Date: 2014-06-03 Impact factor: 42.937